Trial Profile

Effect of a fixed dose combination of perindopril and amlodipine on patients with essential hypertension

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 09 Feb 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Perindopril/amlodipine (Primary)
Indications Essential hypertension
Focus Therapeutic Use
Acronyms CONTROL

Most Recent Events

09 Feb 2016 New trial record
30 Jan 2016 Primary endpoint (The percentage of patients with controlled BP (both systolic and diastolic) at study termination (week 12)) has been met, as per the results published in the Clinical Drug Investigation.
30 Jan 2016 Results published in the Clinical Drug Investigation

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com